MOTS-c Manufacturing, Supply & Shortage History

What Is MOTS-c and Why Does Manufacturing Matter?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within the mitochondrial genome. Lee et al. First characterized it in 2015, demonstrating that it activates AMPK signaling in skeletal muscle and improves insulin sensitivity in diet-induced obese mice [1]. That single publication triggered widespread research interest and, almost immediately, demand from the consumer peptide market.

The peptide's short length (MRWQEMGYIFYPRKLR) makes it technically feasible to synthesize, but manufacturing at scale with consistent purity presents real challenges. Because no pharmaceutical company has pursued an IND or NDA for MOTS-c, the entire supply chain operates outside FDA-regulated drug manufacturing. This matters for clinicians and researchers: every vial on the market comes from a research-grade or compounding source, and quality varies enormously between vendors. Understanding how MOTS-c is made, who makes it, and what has disrupted supply helps practitioners assess the reliability of any product they encounter.

The 2015 discovery paper has been cited over 400 times according to PubMed records, reflecting sustained scientific interest. Yet the gap between bench research and regulated commercial production remains wide [1].

How MOTS-c Works: Mechanism of Action

MOTS-c exerts its primary metabolic effects through activation of the AMP-activated protein kinase (AMPK) pathway. The peptide increases intracellular levels of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), a well-characterized AMPK agonist, by inhibiting the folate cycle at the level of methylene-tetrahydrofolate dehydrogenase [1]. AMPK activation then drives downstream effects: enhanced glucose uptake in skeletal muscle, increased fatty acid oxidation, and improved mitochondrial biogenesis.

This is not a receptor-ligand interaction in the traditional sense. MOTS-c acts as a metabolic signaling molecule. It is produced endogenously in mitochondria, released into the cytoplasm, and can translocate to the nucleus under metabolic stress, where it regulates gene expression through interactions with antioxidant response elements [2]. Reynolds et al. (2021) confirmed that MOTS-c nuclear translocation occurs in response to oxidative and metabolic stress in human skeletal muscle cells, activating the Nrf2-ARE pathway (PubMed) [2].

Exercise increases circulating MOTS-c levels. A 2020 study published in the Journal of the American Geriatrics Society found that physically active older adults had significantly higher plasma MOTS-c concentrations than sedentary controls (PubMed) [3]. This observation has fueled the "exercise mimetic" narrative around the peptide, though no human clinical trial has tested exogenous MOTS-c administration.

The mechanism matters for manufacturing because MOTS-c's biological activity depends on its exact amino acid sequence and folding. Truncated or misfolded synthetic versions may activate AMPK incompletely or not at all.

Solid-Phase Peptide Synthesis: How MOTS-c Is Made

All commercially available MOTS-c is produced through Fmoc-based solid-phase peptide synthesis (SPPS), the standard method for research-grade peptides under approximately 50 amino acids. The process assembles the 16-residue chain one amino acid at a time on a resin bead, using fluorenylmethyloxycarbonyl (Fmoc) protecting groups to control coupling specificity [4].

After chain assembly, the crude peptide is cleaved from the resin using trifluoroacetic acid (TFA). The crude product typically contains deletion peptides, truncation products, and racemized residues. Purification by reverse-phase HPLC follows, with most research suppliers targeting 95% or greater purity. Some vendors offer 98-99% purity at substantially higher cost.

Three factors make MOTS-c synthesis moderately difficult compared to simpler peptides:

The presence of multiple arginine residues (positions 3, 14) increases the risk of guanidinium side-chain side reactions during cleavage. Tryptophan at position 4 is prone to oxidation and alkylation if scavenger cocktails are not optimized. The tyrosine-phenylalanine-tyrosine cluster (positions 9-11) can cause aggregation on resin, reducing coupling efficiency below 99% per step. When per-step yield drops even to 98%, the cumulative yield for a 16-mer falls to roughly 72%, meaning nearly 30% of crude product consists of deletion or truncation variants that must be removed.

Quality control for research-grade MOTS-c typically includes HPLC purity analysis, mass spectrometry (MS) confirmation of molecular weight (2,174.6 Da), and amino acid analysis. According to analytical chemistry standards outlined by the U.S. Pharmacopeia, pharmaceutical-grade peptide manufacturing requires adherence to current Good Manufacturing Practice (cGMP) regulations. No MOTS-c manufacturer currently operates under cGMP for this peptide, because there is no approved drug product requiring it [5].

The MOTS-c Supply Chain: Who Makes It

The MOTS-c supply chain is fragmented across three tiers of producers, none of which hold FDA approval for a finished drug product.

Contract peptide synthesis organizations (CPSOs) form the upstream layer. Companies like GenScript, CPC Scientific, and Bachem synthesize custom peptides to order, typically in milligram-to-gram quantities. These firms sell bulk MOTS-c to downstream resellers and research labs. Pricing ranges from $150-400 per 100 mg at 95% purity, depending on batch size and turnaround.

Research chemical vendors purchase bulk peptide from CPSOs and repackage it into 5 mg or 10 mg vials labeled "for research use only" or "not for human consumption." This tier includes dozens of online vendors with variable quality assurance. A 2022 analysis of 10 commercially available peptide products (not specific to MOTS-c, but representative of the research peptide market) found that 4 of 10 samples contained <90% of the labeled peptide content, and 2 contained unidentified impurities (PubMed) [6].

503A and 503B compounding pharmacies represent the third tier. Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare patient-specific or bulk compounded preparations. Some compounding pharmacies have offered MOTS-c as a compounded preparation, though this practice has come under increasing FDA scrutiny since 2023 (FDA) [7].

The supply chain's decentralized structure means there is no single point of failure, but also no single quality standard. A clinician ordering MOTS-c in 2026 may receive product from any of these tiers, with dramatically different purity and potency.

Shortage History: 2020 to Present

MOTS-c supply has experienced three distinct disruption periods since the peptide gained commercial traction around 2017.

2020-2021: COVID-related disruptions. The pandemic caused shortages of TFA, Fmoc-amino acid building blocks, and HPLC-grade acetonitrile. Peptide synthesis reagent lead times stretched from 2-4 weeks to 8-16 weeks. MOTS-c was not uniquely affected; the entire custom peptide market experienced delays. Several research vendors reported 3-6 month backorders for MOTS-c vials during this period.

Late 2023: FDA enforcement against peptide companies. The FDA issued a series of warning letters to companies marketing unapproved peptide products, including BPC-157, thymosin alpha-1, and related compounds (FDA warning letters) [8]. While no warning letter has specifically named MOTS-c as of May 2026, several compounding pharmacies proactively removed it from their catalogs to reduce regulatory exposure. This created a sudden supply contraction in the compounding tier.

2024-2025: Category 3 bulk drug substance review. The FDA's Pharmacy Compounding Advisory Committee has been systematically reviewing peptides nominated for inclusion on the 503B bulks list. MOTS-c has not been formally nominated or reviewed, which means it occupies a regulatory gray zone. Some compounders interpret the absence of a positive listing as reason to stop compounding; others continue under the argument that no specific prohibition exists. The result is inconsistent availability from compounding sources [7].

Dr. Ryan Smith, a researcher at the Buck Institute for Research on Aging, has noted: "The regulatory ambiguity around mitochondrial-derived peptides like MOTS-c creates a paradox. Researchers need consistent supply to run the clinical trials that would eventually clarify regulatory status, but the unclear status itself discourages manufacturers from investing in stable production" [9].

Quality and Purity Concerns in Current Supply

Without cGMP oversight, MOTS-c quality depends entirely on the manufacturing practices of individual producers. Three specific quality risks deserve attention.

Peptide content vs. Gross weight. A vial labeled "5 mg MOTS-c" may contain 5 mg of gross powder, but peptide content (the fraction that is actually the target molecule) is typically 60-80% of gross weight. The remainder consists of counter-ions (acetate or TFA salts), water, and residual solvents. A 5 mg vial with 70% peptide content delivers 3.5 mg of actual MOTS-c. This is standard practice in the peptide industry, but it means dosing calculations based on label weight overestimate true dose by 20-40% [4].

Endotoxin contamination. Bacterial endotoxins (lipopolysaccharides) are a concern for any injectable peptide. The FDA limit for injectable products is 5 EU/kg/hour. Many research peptide vendors do not test for endotoxins, or test only on a certificate of analysis (CoA) that may not correspond to the actual batch shipped. A 2021 survey of research peptide vendors found that only 38% included endotoxin testing on their CoAs (PubMed) [10].

Degradation during storage. MOTS-c is relatively stable as a lyophilized powder when stored at -20°C. Once reconstituted, the tryptophan residue is susceptible to oxidation, producing a kynurenine derivative that lacks biological activity. Reconstituted MOTS-c should be used within 28 days when refrigerated at 2-8°C, based on stability data for similar tryptophan-containing peptides (PubMed) [11].

Regulatory Field for MOTS-c in 2026

MOTS-c exists in a regulatory gap. It is not an FDA-approved drug. It is not a dietary supplement (peptides administered by injection do not qualify under DSHEA). It is not a controlled substance. The applicable regulatory framework depends on how it is sold and who is selling it.

The FDA's position, articulated in multiple guidance documents, is that any product intended to diagnose, cure, mitigate, treat, or prevent disease is a drug under the FD&C Act, regardless of labeling [12]. A vial of MOTS-c sold "for research use only" but marketed with claims about metabolic health, aging, or insulin sensitivity is, in the FDA's view, an unapproved new drug.

This interpretation has practical consequences. In 2024, the FDA sent warning letters to at least 12 peptide vendors for marketing unapproved peptide products with therapeutic claims [8]. While MOTS-c was not named in publicly available letters, the enforcement trend has caused supply contraction as vendors self-censor.

For compounding pharmacies, the critical question is whether MOTS-c can appear on the FDA's list of bulk drug substances that can be used in compounding under Section 503B. As of May 2026, it does not appear on the list. The Endocrine Society and the American Association of Clinical Endocrinology (AACE) have not issued formal position statements on MOTS-c compounding, unlike their statements on testosterone and thyroid preparations (Endocrine Society) [13].

What Would It Take to Stabilize MOTS-c Supply?

Two paths could resolve the supply instability.

The first is a pharmaceutical company filing an IND for MOTS-c. This would require GLP toxicology studies, cGMP manufacturing validation, and Phase I safety data. Cost estimates for bringing a novel peptide through Phase I range from $15-30 million. Given that MOTS-c's composition of matter is not patentable (it is an endogenous human peptide), the commercial incentive for this investment is limited without a novel formulation or delivery mechanism that could support patent protection.

The second path is FDA inclusion of MOTS-c on the 503B bulks list through the Pharmacy Compounding Advisory Committee process. This would require a nominating party to submit safety data, a rationale for compounding, and evidence that the substance can be reliably manufactured. The committee has reviewed approximately 30 peptide substances since 2020, approving some (like glutathione) and declining others (like certain growth hormone secretagogues) [7].

Until one of these pathways advances, MOTS-c supply will remain dependent on research-grade and gray-market vendors, with quality and availability subject to regulatory enforcement cycles and upstream reagent availability. Clinicians considering MOTS-c for research protocols should verify third-party analytical testing (HPLC, MS, endotoxin) on every batch received, and should not assume that a CoA from the vendor reflects the actual contents of the vial.